For the Inventor, By the Inventor

Enter assignee name

Grand Cayman, Cayman Islands

Beigene, Ltd.

USPTO Granted Patents = 54

% Expired Patents = 7.4

CIPO Patents = 8

EPO Patents = 18

Trademarks = 5

Forward Citations = 664

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Changyou Zhou (26 out of 45 patents)

Zhiwei Wang (18 out of 78 patents)

Guoliang Zhang (15 out of 23 patents)

4. Hexiang Wang (14 out of 18 patents)

5. Yunhang Guo (12 out of 25 patents)

6. Bo Ren (12 out of 13 patents)

7. Kang Li (11 out of 32 patents)

8. Tong Zhang (10 out of 88 patents)

9. Jing Li (7 out of 151 patents)

10. Jing Song (7 out of 15 patents)

11. Qi Liu (5 out of 103 patents)

12. Min Wei (4 out of 15 patents)

13. Haibo Zhao (4 out of 4 patents)

14. Hao Peng (4 out of 11 patents)

15. Geoffrey Kim (3 out of 3 patents)

Core Competencies:

Cyclic Dinucleotides

Bcl-2 Inhibitors

TLR7 Agonists

HPK1 Inhibitors

Anti-OX40 Antibodies

Immunotherapy

A2A Receptor Antagonists

BTK Inhibitors

PARP Inhibitors

Anti-PD-L1 Antibodies

Raf Kinase Inhibitors

Indoleamine 2,3-Dioxygenases

54 patents: Sort by Forward Citations

1. 12667560 - Co-administration of mirdametinib and lifirafenib for use in treating cancers (2026-06-30),

2. 12582604 - Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor (2026-03-24),

3. 12435104 - Cyclic dinucleotides as sting agonists (2025-10-07),

4. 12286430 - Bcl-2 inhibitor (2025-04-29),

5. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2025-04-21),

6. 12195449 - 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof (2025-01-14),

7. 12103974 - Anti-OX40 antibodies and methods of use (2024-10-01),

8. 12077536 - BCL-2 inhibitors (2024-09-03),

9. 11905294 - Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors (2024-02-20),

10. 11875885 - Interoperable platform for reducing redundancy in medical database management (2024-01-16),

11. 11725012 - Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors (2023-08-15),

12. 11636930 - Interoperable platform for reducing redundancy in medical database management (2023-04-25),

13. 11597768 - Immunotherapy for hepatocellular carcinoma (2023-03-07),

14. 11555038 - Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-01-17),

15. 11512132 - Anti-PD-L1 antibodies and their use as therapeutics and diagnostics (2022-11-29),

BeiGene, Ltd. is a commercial-stage biotechnology company that focuses on developing and commercializing innovative medicines for cancer treatment. With a global presence, BeiGene combines cutting-edge science and technology to discover, develop, and deliver globally accessible oncology drugs. The company is committed to improving treatment outcomes and patient lives through its pipeline of targeted and immuno-oncology therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

54 Patents

#19 in Grand Cayman

#23 in Cayman Islands

#13,083 in the World

Grand Cayman, Cayman Islands

Beigene, Ltd.

Forward Citations = 664

44 inventors:

Changyou Zhou (26 out of 45 patents)

Zhiwei Wang (18 out of 78 patents)

Guoliang Zhang (15 out of 23 patents)

4. Hexiang Wang (14 out of 18 patents)

5. Yunhang Guo (12 out of 25 patents)

Please report any incorrect information to [email protected]

Loading…